The 2026 Nobel Prize in Chemistry was awarded to Henri Kagan and Kensō Soai for decoding the enigma of nature's chemical asymmetry, a discovery that promises to transform how we manufacture pharmaceuticals and materials.

Some molecules have a property called chirality, meaning they exist in two mirror-image forms that are not identical. Living organisms almost exclusively contain one of these forms, a phenomenon known as homochirality. The difference between these molecular twins can be as subtle as a lock that only fits one key.

While one enantiomer of a chiral molecule might produce the desired therapeutic effect, the other can cause harmful side effects. Scientists have long struggled to control which version of the molecule they end up with in their synthesis. Kagan and Soai's work offers a solution, opening up new avenues for precise control in chemical reactions.

Kagan’s research in the 1980s focused on refining asymmetric reactions through a detailed study of the catalyst, while Soai sought to create a reaction in which the product itself would act as a catalyst. In 2003, Soai achieved a breakthrough, creating a reaction that produced near-absolute purity of one of the enantiomers, mimicking the homochirality found in living organisms.

This discovery not only advances our understanding of chemistry but also has practical implications. It could lead to more effective and safer drugs, tailored to the specific needs of our bodies. The Nobel Committee praised the work for its 'practical interest and its invaluable tool for studying reaction mechanisms.'